ClinVar Miner

Submissions for variant NM_007294.3(BRCA1):c.4243del (p.Glu1415fs) (rs80357981)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 10
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) RCV000031159 SCV000300095 pathogenic Breast-ovarian cancer, familial 1 2016-09-08 reviewed by expert panel curation Variant allele predicted to encode a truncated non-functional protein.
Ambry Genetics RCV000217565 SCV000274996 pathogenic Hereditary cancer-predisposing syndrome 2017-05-09 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Alterations resulting in premature truncation (e.g.reading frame shift, nonsense)
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), c/o University of Cambridge RCV000031159 SCV000325906 pathogenic Breast-ovarian cancer, familial 1 2015-10-02 criteria provided, single submitter clinical testing
GeneDx RCV000482127 SCV000566521 pathogenic not provided 2018-03-29 criteria provided, single submitter clinical testing This deletion of one nucleotide in BRCA1 is denoted c.4243delG at the cDNA level and p.Glu1415LysfsX4 (E1415KfsX4) at the protein level. Using alternate nomenclature, this variant would be defined as BRCA1 c.4362delG. The normal sequence, with the base that is deleted in brackets, is ACTA[delG]AAGC. The deletion causes a frameshift, which changes a Glutamic Acid to a Lysine at codon 1415, and creates a premature stop codon at position 4 of the new reading frame. This variant is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. BRCA1 c.4243delG has been observed in at least four breast and/or ovarian cancer families and in an individual with endometrial cancer (Konecny 2011, Smith 2011, Lu 2015). In an HDR activity assay, BRCA1 c.4243delG demonstrated significantly reduced HDR activity relative to wild type (Lu 2015). We consider this variant to be pathogenic.
Department of Pathology and Laboratory Medicine,Sinai Health System RCV000496518 SCV000591499 pathogenic Hereditary breast and ovarian cancer syndrome 2014-12-10 criteria provided, single submitter clinical testing
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000482127 SCV000883469 pathogenic not provided 2017-11-20 criteria provided, single submitter clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000482127 SCV000888913 pathogenic not provided 2018-03-06 criteria provided, single submitter clinical testing
Sharing Clinical Reports Project (SCRP) RCV000031159 SCV000053759 pathogenic Breast-ovarian cancer, familial 1 2012-06-15 no assertion criteria provided clinical testing
Breast Cancer Information Core (BIC) (BRCA1) RCV000031159 SCV000145038 pathogenic Breast-ovarian cancer, familial 1 2003-07-22 no assertion criteria provided clinical testing
Research Molecular Genetics Laboratory,Women's College Hospital, University of Toronto RCV000496518 SCV000587384 pathogenic Hereditary breast and ovarian cancer syndrome 2014-01-31 no assertion criteria provided research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.